Sara Bonstein Biography and Net Worth

CFO of Insmed

Sara joined Insmed in January 2020, bringing more than 15 years of operational and financial leadership in the life sciences industry. Sara has extensive experience leading public biotech companies as CFO. Prior to joining Insmed, she served as the Chief Financial Officer, Chief Operating Officer, and Corporate Secretary at OncoSec Medical and as the Chief Financial Officer, Secretary, Treasurer, and Executive Vice President at Advaxis, Inc. In these roles, Sara raised over $300 million in the capital marketplace and licensing deals. She also established strong financial controls, streamlined business operations, and was responsible for the overall leadership and management of operations, including corporate finance, investor relations, business development, IT, facilities, legal, and human resources. At Eli Lilly & Company, Sara was a Six Sigma Champion and Black Belt. Prior to her Six Sigma role, she was the Director of Finance at Eli Lilly and ImClone, and before that she was a financial analyst at Johnson & Johnson. In 2016, NJBiz named Sara CFO of the Year – Healthcare Organization and Forty under 40. Sara is a graduate of Johnson & Johnson’s Financial Leadership Development Program. She holds a BS in Finance from The College of New Jersey and an M.B.A. from Rider University. Sara is a member of the board of directors of scPharmaceuticals Inc. (Nasdaq: SCPH) and Xilio Therapeutics, Inc. (Nasdaq: XLO).

What is Sara Bonstein's net worth?: The estimated net worth of Sara Bonstein is at least $15.07 million as of July 21st, 2025. Ms. Bonstein owns 73,505 shares of Insmed stock worth more than $15,071,465 as of December 4th. This net worth evaluation does not reflect any other investments that Ms. Bonstein may own. Learn More about Sara Bonstein's net worth.
How do I contact Sara Bonstein?: The corporate mailing address for Ms. Bonstein and other Insmed executives is 700 US Highway 202/206, Bridgewater NJ, 08807. Insmed can also be reached via phone at 908-977-9900 and via email at [email protected]. Learn More on Sara Bonstein's contact information.
Has Sara Bonstein been buying or selling shares of Insmed?: Sara Bonstein has not been actively trading shares of Insmed during the last quarter. Most recently, Sara Bonstein sold 58,400 shares of the business's stock in a transaction on Monday, July 21st. The shares were sold at an average price of $102.67, for a transaction totalling $5,995,928.00. Following the completion of the sale, the chief financial officer now directly owns 73,505 shares of the company's stock, valued at $7,546,758.35. Learn More on Sara Bonstein's trading history.
Who are Insmed's active insiders?: Insmed's insider roster includes Roger Adsett (COO), Elizabeth Anderson (Director), Sara Bonstein (CFO), David Brennan (Director), Clarissa Desjardins (Director), Clarissa Desjardins (Director), Martina Flammer (Insider), Leo Lee (Director), William Lewis (CEO), David McGirr (Director), Orlov Nicole Schaeffer (Insider), Melvin Sharoky (Director), Michael Smith (VP), and John Wise (Insider). Learn More on Insmed's active insiders.
Are insiders buying or selling shares of Insmed?: In the last year, Insmed insiders bought shares 2 times. They purchased a total of 3,025 shares worth more than $201,694.15. In the last year, insiders at the biopharmaceutical company sold shares 74 times. They sold a total of 1,482,921 shares worth more than $149,825,544.11. The most recent insider tranaction occured on November, 24th when Director Elizabeth M Anderson sold 5,000 shares worth more than $1,022,900.00. Insiders at Insmed own 3.0% of the company. Learn More about insider trades at Insmed.
Information on this page was last updated on 11/24/2025.

Sara Bonstein Insider Trading History at Insmed

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/21/2025	Sell	58,400	$102.67	$5,995,928.00	73,505
7/7/2025	Sell	57,764	$95.86	$5,537,257.04	84,017
6/23/2025	Sell	57,765	$101.78	$5,879,321.70	93,536
6/10/2025	Sell	57,766	$89.12	$5,148,105.92	103,412
6/3/2025	Sell	1,579	$71.50	$112,898.50	113,288
5/14/2025	Sell	1,634	$65.61	$107,206.74	108,359
5/13/2025	Sell	8,870	$67.81	$601,474.70	109,993
2/18/2025	Sell	18,322	$80.31	$1,471,439.82	118,863
2/11/2025	Sell	13,302	$80.00	$1,064,160.00	142,204
2/6/2025	Sell	28,390	$80.90	$2,296,751.00	155,506
1/10/2025	Sell	1,066	$63.72	$67,925.52	118,863
1/7/2025	Sell	3,470	$65.70	$227,979.00	114,736
5/29/2024	Sell	220,564	$50.00	$11,028,200.00	117,481
5/14/2024	Sell	11,088	$25.32	$280,748.16	117,481
1/9/2024	Sell	4,497	$29.18	$131,222.46	114,051
12/22/2023	Sell	13,199	$30.00	$395,970.00	105,241
1/10/2023	Sell	2,857	$18.12	$51,768.84	66,031
1/11/2022	Sell	1,154	$25.11	$28,976.94

Sara Bonstein Buying and Selling Activity at Insmed

Insmed Company Overview

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Today's Range

Now: $205.04

$202.68

$208.81

50 Day Range

MA: $179.16

$137.03

$211.41

2 Week Range

Now: $205.04

$60.40

$212.75

Volume

1,861,157 shs

Average Volume

2,592,626 shs

Market Capitalization

$43.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.01